▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Relmada Therapeutics (NASDAQ: RLMD)

$2.66

(23.1%)

$0.50

Price as of October 2, 2025, 4:00 p.m. ET

Relmada Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
RLMD	-33.94%	-94.49%	-44.00%	-96%
S&P	+17.56%	+100.43%	+14.92%	+242%

Relmada Therapeutics Company Info

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

News & Analysis

Featured Article

Here's Why Relmada Therapeutics Stock Popped Today

Results from a human abuse potential study with REL-1017 exceeded expectations.

Cory Renauer | Jul 27, 2021

Featured Article

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

James Halley | Jul 7, 2020

Could Opioids Treat Depression? This Biotech Plans to Find Out

Zhiyuan Sun | May 19, 2020

Should investors be excited or concerned about Relmada Therapeutics' attempt to treat severe depression with a variant of methadone?

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services